Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00732771 | Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism | PHASE2 | COMPLETED | 12 | — | — | Jun 1, 2008 | - | Aug 26, 2009 | 1 | France |
| Arm | Type | Description |
|---|---|---|
| LCI696 1mg bid | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LCI699 | DRUG | - |
Inclusion Criteria: * Diagnosis of primary hyperaldosteronism (PH) within the last 3 years, either with or without an aldosterone producing adenoma (APA). * Hypertension at screening Exclusion Criteria: * Persistent hypokalemia * Renal impairment * Significant hepatic disease * Any surgical or me...